NCT03666832Unknown1 期
Multi-center, Open-label, Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Efficacy of TEW-7197 in Combination With FOLFOX in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine and Nab-Paclitaxel
Joon Oh Park1 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2019年6月17日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- pregression free survival
研究概览
简要总结
- Inclusion
- Subjects who are males or females ≥ 19 years of age
- Subjects who have the following history of first-line gemcitabine and nab-paclitaxel among patients with cytologically or histologically proven metastatic pancreatic ductal adenocarcinoma
- Subjects who can give written informed consent for participation in this trial after receiving explanations of this trial
- Subjects who have the following laboratory test values:
- bilirubin ≤ 1.5 x ULN (upper limit of normal)
- aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5 x ULN
- serum creatinine ≤ 1.5 x ULNor estimated creatinine clearance ≥ 40 mL/min (Cockcroft-Gault)
- partial thromboplastin time (aPTT) ≤ 1.5 x ULN
- absolute neutrophil count (ANC) ≥ 1,500 cells/µL
- platelet count ≥ 100,000/µL
- hemoglobin ≥ 9.0 g/dL
- Subjects who have at least a 12-week life expectancy at the Investigator's discretion
- Subjects who have Eastern Cooperative Oncology Group (ECOG)Performance Status 0-1
- Exclusion
- Subjects who were treated with surgery, radiotherapy, chemotherapy or investigational therapy within 2 weeks (note: placement of biliary stent is allowed)
- Subjects who have uncontrolled CNS metastases (patients who require steroids should be on a stable or decreasing dose for at least 2 weeks)
- Subjects who have any contraindications for 5-FU, leucovorin, or oxaliplatin
- Subjects who have moderate or severe cardiovascular disease
- Subjects who have myocardial infarction, unstable angina pectoris, New York Heart Association (NYHA) Class III/IV congestive heart failure, or uncontrolled hypertension within 6 months before screening
- Subjects who have major abnormalities at the Investigator's discretion based on electrocardiogram (ECG)and Doppler ECHO results at screening or within 14 days before screening
- Subjects who have increase in brain natriuretic peptide(BNP) or increase in troponin (over 99th percentile upper reference limit) at Screening (based on the normal range of relevant study center)
- Subjects who have risk factors for ascending aortic aneurysm such as genetic disorder and trauma and risk factors for aortic stenosis
- Subjects who have a history of heart or aorta surgery
- Subjects who have clinically significant gastrointestinal bleeding within 4 weeks before screening
- Subjects who have a known history or suspected hypersensitivity to any excipients of the investigational product or combination drug(s)
- Subjects who have received prior treatment targeting the signaling pathway of TGF-β
- Subjects who have a disease or condition that affects the mechanism of the investigational product, or are currently using or planning to use:
- Drugs that are exclusively or primarily eliminated by cytochrome P-450 isozyme (CYP) including CYP1A2, CYP2B6, or CYP3A4
- Drugs that are exclusively or primarily eliminated by UDP glucuronyltransferase (UGT) 1A1 (UGT1A1)
- Drugs that are substrates for the drug transporter multidrug resistance protein 1 (MDR1) have a narrow therapeutic window or are strong inhibitors of drug transporter MDR1
- Drugs that are strong inhibitors or inducers of CYP2D6 or CYP3A4
- Subjects who are unable to swallow tablets
- Subjects who have a history of or are suspected of drug abuse
- Female subjects of child-bearing potential who have a positive result on a pregnancy test at screening or are unable to agree to use an effective barrier method of birth control to avoid pregnancy during the study period (e.g., sterilization, intrauterine contraceptive device, combination of oral contraception and barrier contraception, combination of other hormone delivery systems and barrier contraception, contraceptive cream, combination of cream, jelly, or form and diaphragm or condom)
- Subjects, in the opinion of the Investigator, who are unsuitable to participate in the study
- Subjects who were treated with other investigational products within 28 days before screening or within a period shorter than 5-timesthe half-life of the investigational product
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects who are males or females ≥ 19 years of age 2) Subjects who have the following history of first-line gemcitabine and nab-paclitaxel among patients with cytologically or histologically proven metastatic pancreatic ductal adenocarcinoma 3) Subjects who can give written informed consent for participation in this trial after receiving explanations of this trial 4) Subjects who have the following laboratory test values:
- •bilirubin ≤ 1.5 x ULN (upper limit of normal)
- •aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5 x ULN
- •serum creatinine ≤ 1.5 x ULNor estimated creatinine clearance ≥ 40 mL/min (Cockcroft-Gault)
- •partial thromboplastin time (aPTT) ≤ 1.5 x ULN
- •absolute neutrophil count (ANC) ≥ 1,500 cells/µL
- •platelet count ≥ 100,000/µL
- •hemoglobin ≥ 9.0 g/dL 5) Subjects who have at least a 12-week life expectancy at the Investigator's discretion 6) Subjects who have Eastern Cooperative Oncology Group (ECOG)Performance Status 0-1
排除标准
- •Subjects who were treated with surgery, radiotherapy, chemotherapy or investigational therapy within 2 weeks (note: placement of biliary stent is allowed) 2) Subjects who have uncontrolled CNS metastases (patients who require steroids should be on a stable or decreasing dose for at least 2 weeks) 3) Subjects who have any contraindications for 5-FU, leucovorin, or oxaliplatin 4) Subjects who have moderate or severe cardiovascular disease
- •Subjects who have myocardial infarction, unstable angina pectoris, New York Heart Association (NYHA) Class III/IV congestive heart failure, or uncontrolled hypertension within 6 months before screening
- •Subjects who have major abnormalities at the Investigator's discretion based on electrocardiogram (ECG)and Doppler ECHO results at screening or within 14 days before screening
- •Subjects who have increase in brain natriuretic peptide(BNP) or increase in troponin (over 99th percentile upper reference limit) at Screening (based on the normal range of relevant study center)
- •Subjects who have risk factors for ascending aortic aneurysm such as genetic disorder and trauma and risk factors for aortic stenosis
- •Subjects who have a history of heart or aorta surgery 5) Subjects who have clinically significant gastrointestinal bleeding within 4 weeks before screening 6) Subjects who have a known history or suspected hypersensitivity to any excipients of the investigational product or combination drug(s) 7) Subjects who have received prior treatment targeting the signaling pathway of TGF-β 8) Subjects who have a disease or condition that affects the mechanism of the investigational product, or are currently using or planning to use:
- •Drugs that are exclusively or primarily eliminated by cytochrome P-450 isozyme (CYP) including CYP1A2, CYP2B6, or CYP3A4
- •Drugs that are exclusively or primarily eliminated by UDP glucuronyltransferase (UGT) 1A1 (UGT1A1)
- •Drugs that are substrates for the drug transporter multidrug resistance protein 1 (MDR1) have a narrow therapeutic window or are strong inhibitors of drug transporter MDR1
- •Drugs that are strong inhibitors or inducers of CYP2D6 or CYP3A4 9) Subjects who are unable to swallow tablets 10) Subjects who have a history of or are suspected of drug abuse 11) Female subjects of child-bearing potential who have a positive result on a pregnancy test at screening or are unable to agree to use an effective barrier method of birth control to avoid pregnancy during the study period (e.g., sterilization, intrauterine contraceptive device, combination of oral contraception and barrier contraception, combination of other hormone delivery systems and barrier contraception, contraceptive cream, combination of cream, jelly, or form and diaphragm or condom) 12) Subjects, in the opinion of the Investigator, who are unsuitable to participate in the study 13) Subjects who were treated with other investigational products within 28 days before screening or within a period shorter than 5-timesthe half-life of the investigational product
研究组 & 干预措施
Arm1
Experimental
TEW-7197 100mg will be administered orally once a day 5days and rest 2days. Study treatment will be continued until objective disease progression.
干预措施: TEW-7197 (Drug)
结局指标
主要结局
pregression free survival
时间窗: up to 6 weeks
次要结局
未报告次要终点
研究者
Joon Oh Park
Samsung Medical Center
Samsung Medical Center
研究点 (1)
Loading locations...
相似试验
终止
2 期
Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With MyelofibrosisPost-essential Thrombocythemia MyelofibrosisPost-polycythemia Vera MyelofibrosisPrimary MyelofibrosisNCT04854096NS Pharma, Inc.7
已完成
1 期
Study to Evaluate the Safety and Tolerability of FX301 in Patients Undergoing BunionectomyPain, PostoperativeBunionNCT04826328Pacira Pharmaceuticals, Inc85
已完成
1 期
A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's PatientsHealthy Elderly VolunteersMild-to-moderate Alzheimer's Disease PatientsNCT01795339AstraZeneca47
Unknown
2 期
Pyronaridine in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia (AML)Acute Lymphoblastic Leukemia (ALL)NCT05291390Armaceutica, Inc.200
已完成
1 期
Study of Inhaled DMC-IH1 and Intramuscular (EpiPen®) Epinephrine in Healthy Male and Female Participants.Anaphylactic ReactionNCT06013150De Motu Cordis24